Drug ID:Drug152
Drug Name:GLPG1205
CID:71616860
DrugBank ID:DB15346
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT02337608
Molecular Formula:C22H22N2O4
Molecular Weight:378.4 g/mol
Isomeric SMILES:C1CC1C#CC2=CC3=C(C=C2)C4=CC(=NC(=O)N4CC3)OC[C@@H]5COCCO5
Synonyms:GLPG1205; 1445847-37-9; GLPG-1205; K9WR6LRA5D; 4H-Pyrimido(6,1-a)isoquinolin-4-one, 9-(2-cyclopropylethynyl)-2-((2S)-1,4-dioxan-2-ylmethoxy)-6,7-dihydro-; UNII-K9WR6LRA5D; 9-(2-cyclopropylethynyl)-2-[[(2S)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one; compound 122 [WO2013092791A1]; compound 122 (WO2013092791A1); 9-(2-cyclopropylethynyl)-2-(((2S)-1,4-dioxan-2-yl)methoxy)-4H,6H,7H-pyrimido(4,3-a)isoquinolin-4-one
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1192 71616860 Glpg-1205 53831 GPR84 Homo sapiens (human) Negative modulator
dt1193 71616860 Glpg-1205 53831 GPR84 Homo sapiens (human) G-protein coupled receptor 84 negative allosteric modulator
dt1194 71616860 Glpg-1205 53831 GPR84 Homo sapiens (human) Antagonist

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02337608 Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis PHASE2 COMPLETED Galapagos NV Ulcerative Colitis DRUG: GLPG1205|DRUG: Placebo Details
ACTRN12622000579796 A single dose, randomised, 2-period, 2-sequence, crossover, relative bioavailability study comparing 2 x 10 mg R-178 tablets with 2 x 10 mg 2-amino-1,7-dihydro-6H-purine-6-thione tablets administered orally in healthy participants under fasting conditions. PHASE1 None Zenith Technology Corporation Limited 2-amino-1,7-dihydro-6H-purine-6-thione is indicat… Single dose, crossover study design whereby each … Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydro…

PMID: 32902984
Year: 2020
Relationship Type: Treatment Score: 10.0

GPR84 is a medium chain free fatty acid-binding G-protein-coupled receptor associated with inflammatory and fibrotic diseases. As the only reported a…

View Details